nach oben

Cancer Chemotherapy and Pharmacology

Erschienen in:

06.07.2023 | Review Article

Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers

verfasst von: Dongxue Liu, Linlin Hu, Hua Shao

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Abstract

As a new means of oncology treatment, immune checkpoint inhibitors (ICIs) can improve survival rates in patients with resistant or refractory tumors. However, there are obvious inter-individual differences in the unsatisfactory response rate, drug resistance rate and the occurrence of immune-related adverse events (irAE). These questions have sparked interest in researchers looking for a way to screen sensitive populations and predict efficacy and safety. Therapeutic drug monitoring (TDM) is a way to ensure the safety and effectiveness of medication by measuring the concentration of drugs in body fluids and adjusting the medication regimen. It has the potential to be an adjunctive means of predicting the safety and efficacy of ICIs treatment. In this review, the author outlined the pharmacokinetic (PK) characteristics of ICIs in patients. The feasibility and limitations of TDM of ICIs were discussed by summarizing the relationships between the pharmacokinetic parameters and the efficacy, toxicity and biomarkers.

Guo ZS (2018) The 2018 Nobel prize in medicine goes to cancer immunotherapy (editorial for BMC cancer). BMC Cancer 18(1):1086. https://doi.org/10.1186/s12885-018-5020-3CrossRefPubMedPubMedCentral

Yao L, Jia G, Lu L, Bao Y, Ma W (2020) Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. Int Immunopharmacol. https://doi.org/10.1016/j.intimp.2020.106628CrossRefPubMedPubMedCentral

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239CrossRefPubMedPubMedCentral

Jezersek Novakovic B (2016) Checkpoint inhibitors in Hodgkin’s lymphoma. Eur J Haematol 96(4):335–343. https://doi.org/10.1111/ejh.12697CrossRefPubMed

Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56–61. https://doi.org/10.1126/science.aaa8172CrossRefPubMed

Haslam A, Prasad V (2019) Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2(5):e192535. https://doi.org/10.1001/jamanetworkopen.2019.2535CrossRefPubMedPubMedCentral

Sheng J, Srivastava S, Sanghavi K, Lu Z, Schmidt BJ, Bello A, Gupta M (2017) Clinical pharmacology considerations for the development of immune checkpoint inhibitors. J Clin Pharmacol 57(Suppl 10):S26–S42. https://doi.org/10.1002/jcph.990CrossRefPubMed

Gide TN, Wilmott JS, Scolyer RA, Long GV (2018) Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma. Clin Cancer Res 24(6):1260–1270. https://doi.org/10.1158/1078-0432.CCR-17-2267CrossRefPubMed

Mooradian MJ, Sullivan RJ (2019) What to do when Anti-PD-1 therapy fails in patients with melanoma. Oncology (Williston Park) 33(4):141–148PubMed

10.

Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S (2019) Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book 39:147–164. https://doi.org/10.1200/edbk_240837CrossRefPubMed

11.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721–1728. https://doi.org/10.1001/jamaoncol.2018.3923CrossRefPubMedPubMedCentral

12.

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–580. https://doi.org/10.1038/s41571-019-0218-0CrossRefPubMed

13.

Centanni M, Moes D, Troconiz IF, Ciccolini J, van Hasselt JGC (2019) Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet 58(7):835–857. https://doi.org/10.1007/s40262-019-00748-2CrossRefPubMedPubMedCentral

14.

Chinese Pharmacological Society, China-Japan Friendship Hospital (2020) Interpretation of “Pharmacy Expert Consensus on the Therapeutic Drug Monitoring of Antitumor Biosimilars (2020 Edition). Evaluation and Analysis of Drug-Use in Hospitals of China https://doi.org/10.14009/j.issn.1672-2124.2020.05.001.

15.

Caulet M, Lecomte T, Bouché O, Rollin J, Gouilleux-Gruart V, Azzopardi N, Léger J, Borg C, Douillard JY, Manfredi S, Smith D, Capitain O, Ferru A, Moussata D, Terrebone E, Paintaud G, Ternant D (2016) Bevacizumab pharmacokinetics influence overall and progression-free survival in metastatic colorectal cancer patients. Clin Pharmacokinet 55(11):1381–1394. https://doi.org/10.1007/s40262-016-0406-3CrossRefPubMed

16.

Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G (2019) Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Aliment Pharmacol Ther 49(2):147–154. https://doi.org/10.1111/apt.15046CrossRefPubMed

17.

Chatelut E, Hendrikx J, Martin J, Ciccolini J, Moes D (2021) Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology. Pharmacol Res Perspect 9(2):e00757. https://doi.org/10.1002/prp2.757CrossRefPubMedPubMedCentral

18.

Ranchi XU, Miao H, Zheng J (2019) Advances in pharmacokinetic studies of therapeutic monoclonal antibodies and their application. Shanghai Medical & Pharmaceutical Journal

19.

NMPA (2022) Envafolimab-NMPA drug label. https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=64ea07174007353b50394ee573d1e5b0. Accessed 2022-08-09 2022

20.

Ryman JT, Meibohm B (2017) Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol 6(9):576–588. https://doi.org/10.1002/psp4.12224CrossRefPubMedPubMedCentral

21.

Shi LH, Xiao HT (2021) Research progress of therapeutic drug monitoring in the application of immune checkpoint inhibitors. J Cancer Control Treat 34(10):5. https://doi.org/10.3969/j.issn.1674-0904.2021.10.001CrossRef

22.

Ovacik M, Lin K (2018) Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci 11(6):540–552. https://doi.org/10.1111/cts.12567CrossRefPubMedPubMedCentral

23.

Geraud A, Gougis P, Vozy A, Anquetil C, Allenbach Y, Romano E, Funck-Brentano E, Moslehi JJ, Johnson DB, Salem JE (2021) Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance. Annu Rev Pharmacol Toxicol 61:85–112. https://doi.org/10.1146/annurev-pharmtox-022820-093805CrossRefPubMed

24.

Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715–725. https://doi.org/10.1038/nri2155CrossRefPubMed

25.

Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93(11):2645–2668. https://doi.org/10.1002/jps.20178CrossRefPubMed

26.

Peletier LA, Gabrielsson J (2012) Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification. J Pharmacokinet Pharmacodyn 39(5):429–451. https://doi.org/10.1007/s10928-012-9260-6CrossRefPubMedPubMedCentral

27.

FDA FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC. https://www.fda.gov/drugs/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc. Accessed 2018-12-14 2018

28.

FDA FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression. Accessed 2020-05-18 2020

29.

Imamura CK (2019) Therapeutic drug monitoring of monoclonal antibodies: applicability based on their pharmacokinetic properties. Drug Metab Pharmacokinet 34(1):14–18. https://doi.org/10.1016/j.dmpk.2018.11.003CrossRefPubMed

30.

Feng Y, Masson E, Dai D, Parker SM, Berman D, Roy A (2014) Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. Br J Clin Pharmacol 78(1):106–117. https://doi.org/10.1111/bcp.12323CrossRefPubMedPubMedCentral

31.

Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH (2018) Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology 7(5):e1424674. https://doi.org/10.1080/2162402x.2018.1424674CrossRefPubMedPubMedCentral

32.

Zhao X, Suryawanshi S, Hruska M, Feng Y, Wang X, Shen J, Vezina HE, McHenry MB, Waxman IM, Achanta A, Bello A, Roy A, Agrawal S (2017) Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol 28(8):2002–2008. https://doi.org/10.1093/annonc/mdx235CrossRefPubMedPubMedCentral

33.

Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y (2017) Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol 6(1):58–66. https://doi.org/10.1002/psp4.12143CrossRefPubMed

34.

Abe K, Shibata K, Naito T, Otsuka A, Karayama M, Maekawa M, Miyake H, Suda T, Kawakami J (2022) Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients. Eur J Clin Pharmacol 78(1):77–87. https://doi.org/10.1007/s00228-021-03199-6CrossRefPubMed

35.

Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, Jodrell DI, Fearon DT (2016) Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab 24(5):672–684. https://doi.org/10.1016/j.cmet.2016.10.010CrossRefPubMedPubMedCentral

36.

Fearon KC, Glass DJ, Guttridge DC (2012) Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab 16(2):153–166. https://doi.org/10.1016/j.cmet.2012.06.011CrossRefPubMed

37.

Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures JP, Pujol JL, Bommart S (2020) Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer 143:19–26. https://doi.org/10.1016/j.lungcan.2020.03.003CrossRefPubMed

38.

Ahamadi M, Freshwater T, Prohn M, Li CH, de Alwis DP, de Greef R, Elassaiss-Schaap J, Kondic A, Stone JA (2017) Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-pd-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol 6(1):49–57. https://doi.org/10.1002/psp4.12139CrossRefPubMed

39.

Chen Y, Shen Q, Dong M, Xiong Y, Xu H, Li Z (2021) Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome. Front Pharmacol. https://doi.org/10.3389/fphar.2021.725665CrossRefPubMedPubMedCentral

40.

Morrissey KM, Marchand M, Patel H, Zhang R, Wu B, Phyllis Chan H, Mecke A, Girish S, Jin JY, Winter HR, Bruno R (2019) Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother Pharmacol 84(6):1257–1267. https://doi.org/10.1007/s00280-019-03954-8CrossRefPubMedPubMedCentral

41.

Shemesh CS, Chanu P, Jamsen K, Wada R, Rossato G, Donaldson F, Garg A, Winter H, Ruppel J, Wang X, Bruno R, Jin J, Girish S (2019) Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. J Immunother Cancer 7(1):314. https://doi.org/10.1186/s40425-019-0791-xCrossRefPubMedPubMedCentral

42.

Kim ES (2017) Avelumab: first global approval. Drugs 77(8):929–937. https://doi.org/10.1007/s40265-017-0749-6CrossRefPubMed

43.

Desnoyer A, Broutin S, Delahousse J, Maritaz C, Blondel L, Mir O, Chaput N, Paci A (2020) Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 2, immune checkpoint inhibitor antibodies. Eur J Cancer 128:119–128. https://doi.org/10.1016/j.ejca.2020.01.003CrossRefPubMed

44.

Wang CY, Sheng CC, Ma GL, Xu D, Liu XQ, Wang YY, Zhang L, Cui CL, Xu BH, Song YQ, Zhu J, Jiao Z (2021) Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy. Acta Pharmacol Sin 42(8):1368–1375. https://doi.org/10.1038/s41401-020-00550-yCrossRefPubMed

45.

NMPA AiRuiKa-NMPA drug label. https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=16e941d5bc2a443e5353c10cdc1b0404. Accessed 2021–09–13 2021

46.

FDA Libtayo-FDA drug label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761097s007lbl.pdf#page=29. Accessed 2021-02 2021

47.

Yang F, Paccaly AJ, Rippley RK, Davis JD, DiCioccio AT (2021) Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies. J Pharmacokinet Pharmacodyn 48(4):479–494. https://doi.org/10.1007/s10928-021-09739-yCrossRefPubMedPubMedCentral

48.

Costa B, Vale N (2022) Dostarlimab: a review. Biomolecules. https://doi.org/10.3390/biom12081031CrossRefPubMedPubMedCentral

49.

Baverel PG, Dubois VFS, Jin CY, Zheng Y, Song X, Jin X, Mukhopadhyay P, Gupta A, Dennis PA, Ben Y, Vicini P, Roskos L, Narwal R (2018) Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status. Clin Pharmacol Ther 103(4):631–642. https://doi.org/10.1002/cpt.982CrossRefPubMedPubMedCentral

50.

FDA Imfinzi-FDA drug label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s035lbl.pdf#page=31. Accessed 2022–09 2022

51.

Yan T, Yu L, Shangguan D, Li W, Liu N, Chen Y, Fu Y, Tang J, Liao D (2023) Advances in pharmacokinetics and pharmacodynamics of PD-1/PD-L1 inhibitors. Int Immunopharmacol. https://doi.org/10.1016/j.intimp.2022.109638CrossRefPubMed

52.

Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E (2008) Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26(36):5950–5956. https://doi.org/10.1200/JCO.2008.16.1927CrossRefPubMed

53.

Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X (2018) Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 29(11):2208–2213. https://doi.org/10.1093/annonc/mdy408CrossRefPubMedPubMedCentral

54.

Elassaiss-Schaap J, Rossenu S, Lindauer A, Kang SP, de Greef R, Sachs JR, de Alwis DP (2017) Using model-based “learn and confirm” to reveal the pharmacokinetics-pharmacodynamics relationship of pembrolizumab in the KEYNOTE-001 trial. CPT Pharmacometrics Syst Pharmacol 6(1):21–28. https://doi.org/10.1002/psp4.12132CrossRefPubMed

55.

Li H, Yu J, Liu C, Liu J, Subramaniam S, Zhao H, Blumenthal GM, Turner DC, Li C, Ahamadi M, de Greef R, Chatterjee M, Kondic AG, Stone JA, Booth BP, Keegan P, Rahman A, Wang Y (2017) Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response. J Pharmacokinet Pharmacodyn 44(5):403–414. https://doi.org/10.1007/s10928-017-9528-yCrossRefPubMed

56.

FDA (2022) Relatlimab-FDA drug label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf#page=23. Accessed 2022–03 2022

57.

Zhang L, Mai W, Jiang W, Geng Q (2020) Sintilimab: a promising anti-tumor PD-1 antibody. Front Oncol. https://doi.org/10.3389/fonc.2020.594558CrossRefPubMedPubMedCentral

58.

NMPA Tyvyt-NMPA drug label https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=689f2a91727d66c96ace7b1800223f4c. Accessed 2021–06–01 2021

59.

Dhillon S, Duggan S (2022) Sugemalimab: first approval. Drugs 82(5):593–599. https://doi.org/10.1007/s40265-022-01693-4CrossRefPubMed

60.

NMPA Cejemly-NMPA drug label. https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=313b964eb26e738f5bcd1b7310998ccd. Accessed 2022–01–12 2022

61.

Lee A, Keam SJ (2020) Tislelizumab: first approval. Drugs 80(6):617–624. https://doi.org/10.1007/s40265-020-01286-zCrossRefPubMed

62.

NMPA Tislelizumab-NMPA drug label. https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=cca9ba26309c0ee4ff6027951a34bf9d. Accessed 2022–05–18 2022

63.

Tang B, Yan X, Sheng X, Si L, Cui C, Kong Y, Mao L, Lian B, Bai X, Wang X, Li S, Zhou L, Yu J, Dai J, Wang K, Hu J, Dong L, Song H, Wu H, Feng H, Yao S, Chi Z, Guo J (2019) Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients. J Hematol Oncol 12(1):7. https://doi.org/10.1186/s13045-018-0693-2CrossRefPubMedPubMedCentral

64.

Wei XL, Ren C, Wang FH, Zhang Y, Zhao HY, Zou BY, Wang ZQ, Qiu MZ, Zhang DS, Luo HY, Wang F, Yao S, Xu RH (2020) A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors. Cancer Commun (Lond) 40(8):345–354. https://doi.org/10.1002/cac2.12068CrossRefPubMed

65.

NMPA Toripalimab-NMPA drug label. https://www.cde.org.cn/main/xxgk/postmarketpage?acceptidCODE=4a1aa099a4d8745593e4b2adc1081b1a. Accessed 2021–11–24 2021

66.

Wang E, Kang D, Bae KS, Marshall MA, Pavlov D, Parivar K (2014) Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma. J Clin Pharmacol 54(10):1108–1116. https://doi.org/10.1002/jcph.309CrossRefPubMed

67.

Zhu XY, Li ZY, Tian X, Zhang XJ (2021) Research progress of monoclonal antibodies in pharmacokinetic characteristics, analysis methods and method validation. Chin J Clin Pharm Ther 26(1):113–120. https://doi.org/10.12092/j.issn.1009-2501.2021.01.015CrossRef

68.

XJ Wang, YL Liu, DX Wang, Q Zhu, YG Cheng (2016) Development and application of ELISA method for quantitative detection of PD-1 monoclonal antibody. Immunological Journal https://doi.org/10.13431/j.cnki.immunol.j.20160139.

69.

Zheng FJ, Jia ZJ, Xie XY, Han M, Dong LH (2020) A surey of bioanalysis method for antibody drugs. Chin J Clin Pharm Ther 25(2):227–232. https://doi.org/10.12092/j.issn.1009-2501.2020.02.017CrossRef

70.

Wang SJ, Wu ST, Gokemeijer J, Fura A, Krishna M, Morin P, Chen G, Price K, Wang-Iverson D, Olah T, Weiner R, Tymiak A, Jemal M (2012) Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. Anal Bioanal Chem 402(3):1229–1239. https://doi.org/10.1007/s00216-011-5527-9CrossRefPubMed

71.

Law WS, Genin JC, Miess C, Treton G, Warren AP, Lloyd P, Dudal S, Krantz C (2014) Use of generic LC-MS/MS assays to characterize atypical PK profile of a biotherapeutic monoclonal antibody. Bioanalysis 6(23):3225–3235. https://doi.org/10.4155/bio.14.167CrossRefPubMed

72.

Marin C, Khoudour N, Millet A, Lebert D, Bros P, Thomas F, Ternant D, Lacarelle B, Guitton J, Ciccolini J, Blanchet B (2021) Cross-validation of a multiplex LC-MS/MS method for assaying mAbs plasma levels in patients with cancer: a GPCO-UNICANCER study. Pharmaceuticals (Basel). https://doi.org/10.3390/ph14080796CrossRefPubMedPubMedCentral

73.

Iwamoto N, Shimada T (2019) Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach. Drug Metab Pharmacokinet 34(1):19–24. https://doi.org/10.1016/j.dmpk.2018.10.002CrossRefPubMed

74.

Corporation W (2018) ProteinWorks™ eXpress Digest Kits-Care and Use Manual. https://www.waters.com/webassets/cms/support/docs/715004970en.pdf. Accessed 2018–02 2018

75.

Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, Lu JF, Kamerud J, Ahene A, Myler H, Rogers C (2011) Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. Aaps j 13(1):99–110. https://doi.org/10.1208/s12248-011-9251-3CrossRefPubMedPubMedCentral

76.

Kuang B, King L, Wang HF (2010) Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2(6):1125–1140. https://doi.org/10.4155/bio.10.64CrossRefPubMed

77.

YX Gao (2020) Quantitative bioanalysis by LC-MS/MS methods and pharmacokinetic studies of two monoclonal antibodies. Dissertation, University of Chinese Academy of Sciences

78.

Feng Y, Roy A, Masson E, Chen TT, Humphrey R, Weber JS (2013) Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res 19(14):3977–3986. https://doi.org/10.1158/1078-0432.CCR-12-3243CrossRefPubMed

79.

Bellesoeur A, Ollier E, Allard M, Hirsch L, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Tiako M, Khoudour N, Chapron J, Giraud F, Wislez M, Damotte D, Lupo A, Vidal M, Alexandre J, Goldwasser F, Tod M, Blanchet B (2019) Is there an exposure-response relationship for Nivolumab in real-world NSCLC patients? Cancers (Basel). https://doi.org/10.3390/cancers11111784CrossRefPubMed

80.

Basak EA, Koolen SLW, Hurkmans DP, Schreurs MWJ, Bins S, Oomen-de Hoop E, Wijkhuijs AJM, Besten ID, Sleijfer S, Debets R, van der Veldt AAM, Aerts J, Mathijssen RHJ (2019) Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer. Eur J Cancer 109:12–20. https://doi.org/10.1016/j.ejca.2018.12.008CrossRefPubMed

81.

Peer CJ, Heiss BL, Goldstein DA, Goodell JC, Figg WD, Ratain MJ (2022) Pharmacokinetic simulation analysis of less frequent Nivolumab and pembrolizumab dosing: pharmacoeconomic rationale for dose deescalation. J Clin Pharmacol 62(4):532–540. https://doi.org/10.1002/jcph.1984CrossRefPubMedPubMedCentral

82.

Baverel P, Roskos L, Tatipalli M, Lee N, Stockman P, Taboada M, Vicini P, Horgan K, Narwal R (2019) Exposure-response analysis of overall survival for tremelimumab in unresectable malignant mesothelioma: the confounding effect of disease status. Clin Transl Sci 12(5):450–458. https://doi.org/10.1111/cts.12633CrossRefPubMedPubMedCentral

83.

Center for Drug Evaluation and Research [CDER] UF KEYTRUDA Multi-discipline review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761078Orig1s000MultidisciplineR.pdf. Accessed 2016–02–01 2016

84.

Hurkmans DP, Basak EA, van Dijk T, Mercieca D, Schreurs MWJ, Wijkhuijs AJM, Bins S, Hoop EO, Debets R, Joerger M, Odink A, van der Veldt AAM, van der Leest CH, Aerts J, Mathijssen RHJ, Koolen SLW (2019) A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunother Cancer 7(1):192. https://doi.org/10.1186/s40425-019-0669-yCrossRefPubMedPubMedCentral

85.

Liu C, Yu J, Li H, Liu J, Xu Y, Song P, Liu Q, Zhao H, Xu J, Maher VE, Booth BP, Kim G, Rahman A, Wang Y (2017) Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther 101(5):657–666. https://doi.org/10.1002/cpt.656CrossRefPubMed

86.

Hurkmans DP, Sassen SDT, de Joode K, Putter L, Basak EA, Wijkhuijs AJM, Joerger M, Debets R, Koch BCP, Van der Leest CH, Schreurs MWJ, van der Veldt AAM, Aerts J, Mathijssen RHJ, Koolen SLW (2021) Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002344CrossRefPubMedPubMedCentral

87.

Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, Sinha V, de Alwis DP, Stone JA (2018) Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res 24(23):5841–5849. https://doi.org/10.1158/1078-0432.Ccr-18-0415CrossRefPubMed

88.

Wilkins JJ, Brockhaus B, Dai H, Vugmeyster Y, White JT, Brar S, Bello CL, Neuteboom B, Wade JR, Girard P, Khandelwal A (2019) Time-varying clearance and impact of disease state on the pharmacokinetics of avelumab in merkel cell carcinoma and urothelial carcinoma. CPT Pharmacometrics Syst Pharmacol 8(6):415–427. https://doi.org/10.1002/psp4.12406CrossRefPubMedPubMedCentral

89.

FDA (2016) Center for Drug Evaluation and Research. OPDIVO Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125527Orig1s000ClinPharmR.pdf. Accessed 2016–09–30 2016

90.

FDA (2014) Center for Drug Evaluation and Research. KEYTRUDA Clinical Pharmacology and Biopharmaceutics Review. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000TOC.cfm. Accessed 2014–10–02 2014

91.

Yin J, Wu Y, Yang X, Gan L, Xue J (2022) Checkpoint inhibitor pneumonitis induced by Anti-PD-1/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism. Front Immunol. https://doi.org/10.3389/fimmu.2022.830631CrossRefPubMedPubMedCentral

92.

Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, Abidoye O, Teng SL, Lin WT, Dayog S, Bruno R, Jin J, Girish S (2017) Clinical Pharmacokinetics and pharmacodynamics of Atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther 102(2):305–312. https://doi.org/10.1002/cpt.587CrossRefPubMed

93.

Jin C ZY, Jin X, et al. (2017) Exposure-efficacy and safety analysis of durvalumab in patients with urothelial carcinoma (UC) and other solid tumors. J Clin Oncol 35

94.

Agrawal S, Feng Y, Roy A, Kollia G, Lestini B (2016) Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 4:72. https://doi.org/10.1186/s40425-016-0177-2CrossRefPubMedPubMedCentral

95.

Chatterjee M, Turner DC, Felip E, Lena H, Cappuzzo F, Horn L, Garon EB, Hui R, Arkenau HT, Gubens MA, Hellmann MD, Dong D, Li C, Mayawala K, Freshwater T, Ahamadi M, Stone J, Lubiniecki GM, Zhang J, Im E, De Alwis DP, Kondic AG, Fløtten Ø (2016) Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. Ann Oncol 27(7):1291–1298. https://doi.org/10.1093/annonc/mdw174CrossRefPubMedPubMedCentral

96.

Song P, Zhang D, Cui X, Zhang L (2020) Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients. Thorac Cancer 11(9):2406–2430. https://doi.org/10.1111/1759-7714.13541CrossRefPubMedPubMedCentral

97.

Yi M, Jiao D, Xu H, Liu Q, Zhao W, Han X, Wu K (2018) Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. Mol Cancer 17(1):129. https://doi.org/10.1186/s12943-018-0864-3CrossRefPubMedPubMedCentral

98.

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE (2017) Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol 35(35):3924–3933. https://doi.org/10.1200/jco.2017.74.3062CrossRefPubMedPubMedCentral

99.

Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G Jr, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crinò L (2018) Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29(4):959–965. https://doi.org/10.1093/annonc/mdy041CrossRefPubMed

100.

Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, Hahn NM, de Wit R, Pang L, Savage MJ, Perini RF, Keefe SM, Bajorin D, Bellmunt J (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18(11):1483–1492. https://doi.org/10.1016/s1470-2045(17)30616-2CrossRefPubMed

101.

Schumacher TN, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348(6230):69–74. https://doi.org/10.1126/science.aaa4971CrossRefPubMed

102.

Chen YP, Zhang Y, Lv JW, Li YQ, Wang YQ, He QM, Yang XJ, Sun Y, Mao YP, Yun JP, Liu N, Ma J (2017) Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: immunotherapeutic implications. Theranostics 7(14):3585–3594. https://doi.org/10.7150/thno.21471CrossRefPubMedPubMedCentral

103.

Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, Nosho K, Nowak JA, Lawrence MS, Giovannucci EL, Chan AT, Ng K, Meyerhardt JA, Van Allen EM, Getz G, Gabriel SB, Lander ES, Wu CJ, Fuchs CS, Ogino S, Garraway LA (2016) Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 15(4):857–865. https://doi.org/10.1016/j.celrep.2016.03.075CrossRefPubMedPubMedCentral

104.

Ready N, Hellmann MD, Awad MM, Otterson GA, Gutierrez M, Gainor JF, Borghaei H, Jolivet J, Horn L, Mates M, Brahmer J, Rabinowitz I, Reddy PS, Chesney J, Orcutt J, Spigel DR, Reck M, O’Byrne KJ, Paz-Ares L, Hu W, Zerba K, Li X, Lestini B, Geese WJ, Szustakowski JD, Green G, Chang H, Ramalingam SS (2019) First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers. J Clin Oncol 37(12):992–1000. https://doi.org/10.1200/jco.18.01042CrossRefPubMedPubMedCentral

105.

Singal G, Miller PG, Agarwala V, Li G, Kaushik G, Backenroth D, Gossai A, Frampton GM, Torres AZ, Lehnert EM, Bourque D, O’Connell C, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Alpha-Cobb G, Guria A, He J, Frank S, Nunnally AC, Bailey M, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller VA (2019) Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database. JAMA 321(14):1391–1399. https://doi.org/10.1001/jama.2019.3241CrossRefPubMedPubMedCentral

106.

Huang D, Zhang F, Tao H, Zhang S, Ma J, Wang J, Liu Z, Cui P, Chen S, Huang Z, Wu Z, Zhao L, Hu Y (2020) Tumor mutation burden as a potential biomarker for PD-1/PD-L1 inhibition in advanced non-small cell lung cancer. Target Oncol 15(1):93–100. https://doi.org/10.1007/s11523-020-00703-3CrossRefPubMed

107.

Yamashita H, Nakayama K, Ishikawa M, Nakamura K, Ishibashi T, Sanuki K, Ono R, Sasamori H, Minamoto T, Iida K, Sultana R, Ishikawa N, Kyo S (2018) Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. Oncotarget 9(5):5652–5664. https://doi.org/10.18632/oncotarget.23790CrossRefPubMed

108.

Xiao X, Dong D, He W, Song L, Wang Q, Yue J, Xie L (2018) Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer. Gynecol Oncol 149(1):146–154. https://doi.org/10.1016/j.ygyno.2018.02.009CrossRefPubMed

109.

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409–413. https://doi.org/10.1126/science.aan6733CrossRefPubMedPubMedCentral

110.

Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Pedamallu CS, Lazar AJ, Sakai R, Thorsson V, Bass AJ, Laird PW (2018) Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell 33(4):721-735.e728. https://doi.org/10.1016/j.ccell.2018.03.010CrossRefPubMedPubMedCentral

111.

Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK (2018) Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med 24(9):1449–1458. https://doi.org/10.1038/s41591-018-0101-zCrossRefPubMed

112.

Iijima Y, Hirotsu Y, Amemiya K, Higashi S, Miyashita Y, Omata M (2017) Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. Respir Med Case Rep 22:31–33. https://doi.org/10.1016/j.rmcr.2017.05.015CrossRefPubMedPubMedCentral

113.

Cabel L, Riva F, Servois V, Livartowski A, Daniel C, Rampanou A, Lantz O, Romano E, Milder M, Buecher B, Piperno-Neumann S, Bernard V, Baulande S, Bieche I, Pierga JY, Proudhon C, Bidard FC (2017) Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann Oncol 28(8):1996–2001. https://doi.org/10.1093/annonc/mdx212CrossRefPubMed

114.

Khagi Y, Goodman AM, Daniels GA, Patel SP, Sacco AG, Randall JM, Bazhenova LA, Kurzrock R (2017) Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor-based immunotherapy. Clin Cancer Res 23(19):5729–5736. https://doi.org/10.1158/1078-0432.Ccr-17-1439CrossRefPubMedPubMedCentral

115.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H (2017) Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol 28(5):1130–1136. https://doi.org/10.1093/annonc/mdx026CrossRefPubMed

116.

Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, Peranec M, Scolyer R, Kefford RF, Rizos H, Carlino MS (2018) Association between circulating tumor DNA and Pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol 4(5):717–721. https://doi.org/10.1001/jamaoncol.2017.5332CrossRefPubMedPubMedCentral

117.

Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS (2017) Soluble PD-L1 as a biomarker in malignant melanoma treated with checkpoint blockade. Cancer Immunol Res 5(6):480–492. https://doi.org/10.1158/2326-6066.Cir-16-0329CrossRefPubMedPubMedCentral

118.

Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S (2017) Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Oncoimmunology 6(5):e1310358. https://doi.org/10.1080/2162402x.2017.1310358CrossRefPubMedPubMedCentral

119.

Oh SY, Kim S, Keam B, Kim TM, Kim DW, Heo DS (2021) Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep 11(1):19712. https://doi.org/10.1038/s41598-021-99311-yCrossRefPubMedPubMedCentral

120.

Nagato T, Ohkuri T, Ohara K, Hirata Y, Kishibe K, Komabayashi Y, Ueda S, Takahara M, Kumai T, Ishibashi K, Kosaka A, Aoki N, Oikawa K, Uno Y, Akiyama N, Sado M, Takei H, Celis E, Harabuchi Y, Kobayashi H (2017) Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunol Immunother 66(7):877–890. https://doi.org/10.1007/s00262-017-1987-xCrossRefPubMed

121.

Ohkuma R, Ieguchi K, Watanabe M, Takayanagi D, Goshima T, Onoue R, Hamada K, Kubota Y, Horiike A, Ishiguro T, Hirasawa Y, Ariizumi H, Tsurutani J, Yoshimura K, Tsuji M, Kiuchi Y, Kobayashi S, Tsunoda T, Wada S (2021) Increased plasma soluble PD-1 concentration correlates with disease progression in patients with cancer treated with anti-PD-1 antibodies. Biomedicines. https://doi.org/10.3390/biomedicines9121929CrossRefPubMedPubMedCentral

122.

Lee WS, Yang H, Chon HJ, Kim C (2020) Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med 52(9):1475–1485. https://doi.org/10.1038/s12276-020-00500-yCrossRefPubMedPubMedCentral

123.

An HJ, Chon HJ, Kim C (2021) Peripheral blood-based biomarkers for immune checkpoint inhibitors. Int J Mol Sci. https://doi.org/10.3390/ijms22179414CrossRefPubMedPubMedCentral

124.

Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Almanza D, Stehr H, Gojenola L, Bonilla RF, Jin MC, Jeon YJ, Tseng D, Liu C, Merghoub T, Neal JW, Wakelee HA, Padda SK, Ramchandran KJ, Das M, Plodkowski AJ, Yoo C, Chen EL, Ko RB, Newman AM, Hellmann MD, Alizadeh AA, Diehn M (2020) Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183(2):363-376.e313. https://doi.org/10.1016/j.cell.2020.09.001CrossRefPubMedPubMedCentral

125.

Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P (2016) Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919–11924. https://doi.org/10.1073/pnas.1611421113CrossRefPubMedPubMedCentral

126.

Borst J, Ahrends T, Bąbała N, Melief CJM, Kastenmüller W (2018) CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol 18(10):635–647. https://doi.org/10.1038/s41577-018-0044-0CrossRefPubMed

127.

Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D (2019) Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. EMBO Mol Med. https://doi.org/10.1252/emmm.201910293CrossRefPubMedPubMedCentral

128.

Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F (2017) Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 28(6):1368–1379. https://doi.org/10.1093/annonc/mdx108CrossRefPubMed

129.

Puca E, Probst P, Stringhini M, Murer P, Pellegrini G, Cazzamalli S, Hutmacher C, Gouyou B, Wulhfard S, Matasci M, Villa A, Neri D (2020) The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8(+) T cell activity and synergizes with immune checkpoint inhibitors. Int J Cancer 146(9):2518–2530. https://doi.org/10.1002/ijc.32603CrossRefPubMed

130.

Zhang F, Luo DL, Chen Y, Yan JH, Luo LQ, Liu J, Liu YH (2020) Expression of pSTAT3 and PD-L1 in extranodal NK/T cell lymphoma and its clinical significance. Zhonghua Bing Li Xue Za Zhi 49(10):999–1002. https://doi.org/10.3760/cma.j.cn112151-20200205-00066CrossRefPubMed

131.

Cho YH, Choi MG, Kim DH, Choi YJ, Kim SY, Sung KJ, Lee JC, Kim SY, Rho JK, Choi CM (2020) Natural killer cells as a potential biomarker for predicting immunotherapy efficacy in patients with non-small cell lung cancer. Target Oncol 15(2):241–247. https://doi.org/10.1007/s11523-020-00712-2CrossRefPubMed

132.

Michailidou D, Khaki AR, Morelli MP, Diamantopoulos L, Singh N, Grivas P (2021) Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. Sci Rep 11(1):9029. https://doi.org/10.1038/s41598-021-88307-3CrossRefPubMedPubMedCentral

133.

Nixon AB, Schalper KA, Jacobs I, Potluri S, Wang IM, Fleener C (2019) Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? J Immunother Cancer 7(1):325. https://doi.org/10.1186/s40425-019-0799-2CrossRefPubMedPubMedCentral

134.

Feng K, Liu Y, Zhao Y, Yang Q, Dong L, Liu J, Li X, Zhao Z, Mei Q, Han W (2020) Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer. https://doi.org/10.1136/jitc-2019-000367CrossRefPubMedPubMedCentral

135.

Bridge JA, Lee JC, Daud A, Wells JW, Bluestone JA (2018) Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer. Front Med (Lausanne) 5:351. https://doi.org/10.3389/fmed.2018.00351CrossRefPubMed

136.

Hoejberg L, Bastholt L, Johansen JS, Christensen IJ, Gehl J, Schmidt H (2012) Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res 22(4):287–293. https://doi.org/10.1097/CMR.0b013e3283550aa5CrossRefPubMed

137.

Valpione S, Pasquali S, Campana LG, Piccin L, Mocellin S, Pigozzo J, Chiarion-Sileni V (2018) Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade. J Transl Med 16(1):94. https://doi.org/10.1186/s12967-018-1467-xCrossRefPubMedPubMedCentral

138.

Sanmamed MF, Perez-Gracia JL, Schalper KA, Fusco JP, Gonzalez A, Rodriguez-Ruiz ME, Oñate C, Perez G, Alfaro C, Martín-Algarra S, Andueza MP, Gurpide A, Morgado M, Wang J, Bacchiocchi A, Halaban R, Kluger H, Chen L, Sznol M, Melero I (2017) Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients. Ann Oncol 28(8):1988–1995. https://doi.org/10.1093/annonc/mdx190CrossRefPubMedPubMedCentral

139.

Giunta EF, Barra G, De Falco V, Argenziano G, Napolitano S, Vitale P, Zanaletti N, Terminiello M, Martinelli E, Morgillo F, Ciardiello D, De Palma R, Ciardiello F, Troiani T (2020) Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Sci Rep 10(1):17626. https://doi.org/10.1038/s41598-020-72711-2CrossRefPubMedPubMedCentral

140.

Khan S, Khan SA, Luo X, Fattah FJ, Saltarski J, Gloria-McCutchen Y, Lu R, Xie Y, Li Q, Wakeland E, Gerber DE (2019) Immune dysregulation in cancer patients developing immune-related adverse events. Br J Cancer 120(1):63–68. https://doi.org/10.1038/s41416-018-0155-1CrossRefPubMed

141.

Koguchi Y, Hoen HM, Bambina SA, Rynning MD, Fuerstenberg RK, Curti BD, Urba WJ, Milburn C, Bahjat FR, Korman AJ, Bahjat KS (2015) Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab. Cancer Res 75(23):5084–5092. https://doi.org/10.1158/0008-5472.Can-15-2303CrossRefPubMed

142.

Koguchi Y, Iwamoto N, Shimada T, Chang SC, Cha J, Curti BD, Urba WJ, Piening BD, Redmond WL (2021) Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002663CrossRefPubMedPubMedCentral

143.

Xu-Welliver M, Carbone DP (2017) Blood-based biomarkers in lung cancer: prognosis and treatment decisions. Transl Lung Cancer Res 6(6):708–712. https://doi.org/10.21037/tlcr.2017.09.08CrossRefPubMedPubMedCentral

144.

Hopkins AM, Rowland A, Kichenadasse G, Wiese MD, Gurney H, McKinnon RA, Karapetis CS, Sorich MJ (2017) Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer 117(7):913–920. https://doi.org/10.1038/bjc.2017.274CrossRefPubMedPubMedCentral

145.

Voss MH, Chen D, Marker M, Hakimi AA, Lee CH, Hsieh JJ, Knox JJ, Voi M, Motzer RJ (2016) Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. Br J Cancer 114(6):642–649. https://doi.org/10.1038/bjc.2016.21CrossRefPubMedPubMedCentral

146.

Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S (2015) Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer 112(6):1088–1097. https://doi.org/10.1038/bjc.2015.61CrossRefPubMedPubMedCentral

147.

Wang R, Shao X, Zheng J, Saci A, Qian X, Pak I, Roy A, Bello A, Rizzo JI, Hosein F, Moss RA, Wind-Rotolo M, Feng Y (2020) A machine-learning approach to identify a prognostic cytokine signature that is associated with Nivolumab clearance in patients with advanced melanoma. Clin Pharmacol Ther 107(4):978–987. https://doi.org/10.1002/cpt.1724CrossRefPubMed

148.

Wang R, Zheng J, Shao X, Ishii Y, Roy A, Bello A, Lee R, Zhang J, Wind-Rotolo M, Feng Y (2019) Development of a prognostic composite cytokine signature based on the correlation with nivolumab clearance: translational PK/PD analysis in patients with renal cell carcinoma. J Immunother Cancer 7(1):348. https://doi.org/10.1186/s40425-019-0819-2CrossRefPubMedPubMedCentral

149.

de Miguel M, Calvo E (2020) Clinical challenges of immune checkpoint inhibitors. Cancer Cell 38(3):326–333. https://doi.org/10.1016/j.ccell.2020.07.004CrossRefPubMed

150.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443–2454. https://doi.org/10.1056/NEJMoa1200690CrossRefPubMedPubMedCentral

151.

Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW (2015) Phase I study of Pembrolizumab (MK-3475; Anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 21(19):4286–4293. https://doi.org/10.1158/1078-0432.Ccr-14-2607CrossRefPubMed

Titel: Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers
verfasst von: Dongxue Liu
Linlin Hu
Hua Shao
Publikationsdatum: 06.07.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 3/2023
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-023-04541-8

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Therapeutic drug monitoring of immune checkpoint inhibitors: based on their pharmacokinetic properties and biomarkers

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2023

Veratricplatin inhibits the progression of hypopharyngeal squamous cell carcinoma FaDu cells in vitro and in vivo

External validation of a tumor growth inhibition-overall survival model in non-small-cell lung cancer based on atezolizumab studies using alectinib data

Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab

Population pharmacokinetics and toxicity correlation analysis of free and liposome-encapsulated doxorubicin in Chinese patients with advanced breast cancer

Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie